Navigating the immunology inflection point

As medicine evolves towards more precise therapies, immunology has experienced rapid growth, outpacing the overall pharmaceutical market by approximately threefold over the past 5 years (CAGR). This evolution is shaped by both business dynamics and scientific breakthroughs, evidenced by:

Pioneering organizations are redefining the expectations for blockbuster brands, sparking fierce competition, leading to a crowded market of second-generation challengers with either pharmacological similarities or increasingly complex and novel mechanisms of action
First-generation targeted treatments have transformed patients’ quality of life, but the improved benefits of efficacy and safety are increasingly being delivered by a new generation of lower-priced biosimilars such that new entrants must work harder to justify their often incremental benefit to stakeholders
Advancements in understanding of the human immune system and the pathophysiology of autoimmune disease has led to the development of potentially transformative next-generation immunomodulatory therapies that have the potential to “reset” the immune system and induce durable long-term remissions (e.g., CD19-targeted CAR-T cells)

As these business realities and scientific advances unfold, innovators must develop a deeper understanding of the fundamental needs and beliefs of key stakeholder segments, tailoring their clinical development and go-to-market strategies to intimately align against these critical insights.

Lumanity brings extensive immunology expertise across the entire product life cycle, offering a wide range of capabilities to support teams in crafting insight-driven, tailored, and actionable strategies. These strategies drive competitive advantage and de-risk the development and launch of new assets into an ever more complex and challenging immunology marketplace.

Deep knowledge across immunomodulatory frontiers

Lumanity has conducted evaluations on a wide range of immunomodulatory drugs, ranging from conventional small molecule and biologic products (e.g., anti-IL23s, anti-IL13s and JAK inhibitors) to next generation advanced therapeutics with transformative potential (e.g., CD19-targeting CAR-T cells, T regulatory cells, antigen-specific immune tolerizing approaches, etc.).

Our consultants have deep expertise in a wide range of autoimmune diseases, including well established markets, as well as rare and/or underserved diseases and many more.

We can help you with:
End-to-end development
Leverage our experience to support assets from early pre-clinical evaluation, to launch and late-stage lifecycle management
Stakeholder understanding
Further shape, deepen and develop understanding of the nature and complexity of your immunology challenges and the fundamental beliefs and motivations of your key stakeholders
Informed decision making
Leverage insights to make informed choices, supported by immunology strategy experts who have a track record of success in supporting commercial success of assets and brands for their programs and companies
Strategic thinking
Pressure test and challenge existing assumptions and support you transforming your strategic thinking
Development to delivery
Structure end-to end programs that flow from insights to strategy and on to executional excellence and ultimate commercial success
Commercial approaches
Partner on the design and delivery of differentiated, segment-specific educational, market shaping and promotional approaches
Our immunology perspectives View all perspectives

Our expertise

Deep scientific and commercialization know-how
Underpinned by our extensive expertise across immunology. Our deeply experienced global team advises on all aspects of asset development, market access and value, and brand commercialization
Fresh perspectives
We help you go beyond the obvious, unlocking the potential of your asset and ensuring confident strategy endorsed by critical stakeholders
Curated experience
We bring a blend of consulting, industry, and scientific expertise, tailored to address your unique challenge
Best-in-class tools, techniques, and co-creation expertise
We are experts in maximizing value, consensus, and critical outputs in stimulating workshop and co-creation environments
Let's talk

We would love to hear your challenge and discuss how our immunology experts can help.

Ellen Edenberg PhD Senior Vice President, Strategy Consulting
Read more about Ellen Edenberg
David Lomb PhD Vice President, Director of Consulting Services, Autoimmune and Inflammatory Disease Co-Lead
Read more about David Lomb
Danielle Marra MBA, MS Vice President, Strategy Consulting, Autoimmune and Inflammatory Disease Co-Lead
Read more about Danielle Marra
Sandy Richardson Principal, Strategy Consulting
Read more about Sandy Richardson
Peter Smith Senior Vice President, Strategy Consulting
Read more about Peter Smith
Alyssa Trigger MEM Senior Vice President, Strategy Consulting
Read more about Alyssa Trigger